Diabetes Care in The Netherlands: - Novo Nordisk

More documents

Recommendations

Info

• Diabetes is a challenging disease for patients– Treatment requires large behavioural change and poses a real risks of side effects– Complications from diabetes are potentially severe (e.g. stroke, kidney disease heart disease)– Fortunately high quality treatment and strict compliance has proven to keep diabetes patients healthy for a long time• Novo Nordisk has asked Booz & Co to perform a study with the objective to identify how our health care system could beimproved to empower professionals in providing high quality of care for diabetes• Better diabetes care has value for patients and society– Improves health of the patient: improving life expectancy and quality of life– Reduces health care cost: prevention, reduction, and delaying of complications– Reduces the demand for increasingly scarce labour health care (ZorgInnovatiePlatfrom projects 450.000 vacant employmentpositions in health care in 2025)– Improves productivity by increasing workforce participation of diabetes patients• This document presents the findings of the study. It is intended to serve as a basis for further discussion with patients, medicalprofessionals, policymakers and insurers8
ContentsSummarized findings and recommendationsThe opportunity• Diabetes is a major and underestimated source of medical costs and lost productivity• Diabetes care in The Netherlands has reached a high level of quality, but there is still opportunity for further improvement• Further improving health of patients may lead to EUR 1.5-2 B of economic benefits in 2020The road• Refine economic incentives to encourage integrated care and quality improvement• Engage employers, UWV and participative care in diabetes care• Engage the patient’s social network to support self management• Introduce conditional market access models for new therapies and medication to assess behavioural impactAppendix: list of sources9
Page 6 and 7: SummaryDiabetes is a serious and de
Page 8: diabetes care. Extra compensation w
Page 13 and 14: 11Diabetes is a major and underesti
Page 15 and 16: 33Further improving health of of di
Page 17 and 18: 22Recommendation 2: Engage employer
Page 19 and 20: 44Recommendation 4: Introduce condi
Page 21 and 22: Already more than 1M diabetes patie
Page 23 and 24: Costs of of complications and treat
Page 25 and 26: Number of patients reaches ~1.4M in
Page 27 and 28: Increase in lost productivity is dr
Page 29 and 30: Diabetes care clearly improved in t
Page 31 and 32: Better compliance can be stimulated
Page 33 and 34: ContentsSummarized findings and rec
Page 37 and 38: Delaying complications saves medica
Page 39 and 40: LimitedLimitedcollaborationcollabor
Page 41 and 42: Individual quality incentives are l
Page 43 and 44: Recommendation 1: Insurer should in
Page 47 and 48: Labour shortage from late nineties
Page 49 and 50: However, curative and participative
Page 53 and 54: Non-compliance leads to severe comp
Page 55: Facilitated patient networks are su
Page 58 and 59: Recommendation 3:Facilitate network
Page 60 and 61:
ContentsSummarized findings and rec
Page 62 and 63:
But new medication could add a lot
Page 64 and 65:
ContentsSummarized findings and rec
Page 66:
Booz & Company is a global manageme
show all

Diabetes Care in The Netherlands: - Novo Nordisk

Create successful ePaper yourself

Delete template?

Save as template?